- Case report
- Open Access
Malignant fibrous histiocytoma originating from the mesorectum: a case report
© Nakayama et al; licensee BioMed Central Ltd. 2011
- Received: 29 July 2010
- Accepted: 2 February 2011
- Published: 2 February 2011
Malignant fibrous histiocytoma (MFH) is a common sarcoma affecting soft tissues of the body, especially of the extremities or trunk. Prognosis of the abdominal MFH is usually poor.
A 52-year-old female presented to our surgical outpatient clinic with a lower abdominal tumor that had been gradually increasing in size. Clinical examination revealed a firm, irregularly surfaced, fixed, painless, child-head-sized tumor located in her lower abdomen. Computed tomography (CT) and magnetic resonance imaging (MRI) of the abdomen revealed a polycystic tumor at the lower abdomen which was 15 × 13 × 11 cm in diameter and encased the colorectum to the left back side. A barium enema and a colonoscopy showed direct invasion to the rectum. In 2001, the tumor had been excised along with a low anterior resection of the rectum because of direct invasion. The origin of this tumor was the mesorectum. The weight of the excised tumor was 1,500 g, including 800 ml of a brown fluid. A histopathological diagnosis revealed a common type of MFH, in which mitotic figures are frequently seen.
This patient has survived without recurrence, for approximately 8 years since the completed tumor resection. It is important to obtain a complete resection during the MFH treatment.
- Barium Enema
- Lower Abdomen
- Malignant Fibrous Histiocytoma
- Complete Tumor Resection
- Colonoscopic Examination
Malignant fibrous histiocytoma (MFH) is a common sarcoma affecting soft tissues of the body, especially of the extremities or trunk [1–3]. The tumor cells are derived from histiocytes capable of fibroblastic transformation . MFH is an aggressive tumor with a high potential of demonstrating metastasis to other parts of the body. The prognosis of patients with abdominal MFH is usually poor .
Primary mesenteric MFH is a rare disease and few cases have been reported in the English literature [6–10]. We herein report a surgical case of MFH that originated from the mesorectum and affected the rectum.
A 52-year-old female presented to our surgical outpatient clinic with a lower abdominal tumor that had been gradually increasing in size. She first noticed a fist sized, painless tumor about four months ago. Clinical examination revealed a firm, irregularly surfaced, fixed, painless, child-head-sized tumor in her lower abdomen. Laboratory data showed that she had a white blood cell count of 5500/mm3, hemoglobin of 8.3 g/dl, hematocrit of 25.4%, platelets count of 429,000/mm3, normal electrolytes, as well as normal blood urea nitrogen levels and the liver function.
The postoperative course was uneventful, and she left the hospital on the 15th postoperative day. A postoperative follow-up CT revealed no recurrence of the MFH in any organs since the resection was completed.
Retroperioneal and mesenteric MFH have been reported to occur in the rate from 5.7% to 16% of the total MFHs cases [1, 2, 5, 11]. Several reports have so far indicated that MFH derived from the retroperitoneum includes mesenteric MFH because it is difficult to determine the true origin of the huge tumor. Due to this condition, mesenteric MFH is very rarely observed [6–10]. In our case, the tumor originated from the mesorectum because the huge tumor was limited to within the capsule of the mesorectum.
MFH is an aggressive tumor with a high potential of metastasis to other parts of the body. The rates of local recurrence and distant metastasis are 44% and 42%, respectively . The most frequent metastatic site is the lung (82%), followed by the lymph nodes (32%) . Although the 5-year survival rate of all MFH patients that underwent surgery is 67.2% , the 5-year survival rate of patients with abdominal MFH is reportedly 14% . On the other hand, the 5-year survival rate of patients with mesenteric MFH has not been reported because the disease is extremely rare. The current treatment of choice for primary MFH is surgical resection which means wide excision of the tumor with an aim for a tumor-free margin. Presently, the efficacy of adjuvant chemotherapy or radiation has not been clear in the case of retroperitoneal and visceral MFH. Therefore, this patient received neither adjuvant chemotherapy nor radiation.
Mesenteric MFH initially grows without any significant clinical symptoms, and finally produces clinical symptoms and signs later when it compresses or invades the adjacent organs . In this case, she noticed the lower abdominal tumor without any symptoms: nevertheless, the tumor size was 15 × 13 × 11 cm and the tumor had directly invaded to the rectum. Therefore, a complete tumor resection combined with a low anterior resection of the rectum was needed. A previous report indicated that colonic lesions of retroperitoneal MFH were detected by a barium enema and colonoscopic examination before the laparotomy . In the present case, rectal ulcers were also identified by a barium enema and colonoscopic examination before the laparotomy. Moreover, a histologic examination of the resected specimen clearly demonstrated a submucosal invasion by the MFH. It is very important that the requirement of the combined resection with other organs is decided before the operation begins.
The efficacy of chemotherapy against advanced or metastatic MFH is still unclear. On the other hand, several phase studies which investigate the efficacy of chemotherapy against advanced or metastatic soft tissue sarcoma including MFH, have been reported [13–16]. These studies indicated that doxorubicin and ifosfamide are the most active agents for the treatment of this clinical condition [13–16]. However, the response rate of these agents has been reported to range between 10% and 36%, and the median overall survival of these agents has been described to be between 10 and 12 months [13–16]. Therefore, in order to obtain an improvement in the survival in the patients with soft tissue sarcoma including MFH, further investigation of the new available agents is thus called for.
This patient has survived without recurrence for approximately 8 years after the completed tumor resection. A complete resection is important to obtain a favorable prognosis for MFH.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Weiss SW, Enzinger FM, Malignant fibrous histiocytoma: An analysis of 200 cases. Cancer. 1978, 41: 2250-2266. 10.1002/1097-0142(197806)41:6<2250::AID-CNCR2820410626>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Enjoji M, Hashimoto H, Tsuneyoshi M, Iwasaki H: Malignant fibrous histiocytoma. A clinicopathological study of 130 cases. Acta Pathol Jpn. 1980, 30: 727-741.PubMedGoogle Scholar
- Ros PR, Viamonte M, Rywlin AM: Malignant fibrous histiocytoma: Mesenchymal tumor of ubiquitous origin. Am J Roentgenol. 1984, 142: 753-759.View ArticleGoogle Scholar
- O'Brien JE, Stout AP: Malignant fibrous xanthoma. Cancer. 1964, 17: 1445-1455.View ArticlePubMedGoogle Scholar
- Kearney MM, Soule EH, Ivins JC: Malignant fibrous histiocytoma: A retrospective study of 167 cases. Cancer. 1980, 45: 167-178. 10.1002/1097-0142(19800101)45:1<167::AID-CNCR2820450127>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- Bodner K, Bodner-Adler B, Mayerhofer S, Gruünberger W, Wierrani F, Czerwenka K, Leodolter S, Mayerhofer K: Malignat fibrous histiocytoma (MFH) of mesentery: A case report. Anticancer Res. 2002, 22: 169-170.Google Scholar
- Hauser H, Beham A, Uranüs S, Frühwieth H, Lederer A, Klimpfinger M: Malignat fibrous histiocytoma of the mesentery--a rare cause of abdominal pain, Case report with a review of literature. Z Gastroenterol. 1993, 31: 735-738.PubMedGoogle Scholar
- Basso M, Codaccipisanelli M, Bovino A, Vietri F, D'Ermo G, De Toma G: Malignant fibrous histiocytoma of the mesentery: Report of two cases and review of the literature. G Chir. 2005, 26: 43-46.PubMedGoogle Scholar
- Shibuya T, Ishida H, Konno K, Komatsuda T, Hamashima Y, Sato M, Masamune O: Sonographic findings of malignant fibrous histiocytoma of mesentery-report of two cases. Eur J Ultrasound. 1998, 8: 207-212. 10.1016/S0929-8266(98)00066-4.View ArticlePubMedGoogle Scholar
- Higa T, Yamada M, Deguchi S, Tamaki S, Muto Y, Nakasone K, Kiyuna M, Toda T: Malignant fibrous histiocytoma of the mesentery: A case report. Ryukyu Med J. 1996, 16: 75-78.Google Scholar
- Pezzi CM, Rawlings MS, Esgro JJ, Pollock RE, Romsdahl MM: Prognostic factors in 277 patients with malignant fibrous histiocytoma. Cancer. 1992, 69: 2098-2103. 10.1002/1097-0142(19920415)69:8<2098::AID-CNCR2820690815>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
- Kobayashi S, Goto K, Shiraki S, Okayama Y, Ando H, Okumura F, Nakamura S, Hattstori T, Joh T, Itoh M: Retroperitoneal malignant fibrous histiocytoma causing variegated colonic lesion. Internal Medicine. 1998, 37: 376-380. 10.2169/internalmedicine.37.376.View ArticlePubMedGoogle Scholar
- Lorigan P, Verweiji J, Papao Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PCW, Blay JY: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metasttic soft tissue sarcoma: A European organization for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol. 2007, 25: 3144-3150. 10.1200/JCO.2006.09.7717.View ArticlePubMedGoogle Scholar
- Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM: Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcoma. J Clin Oncol. 2009, 27: 1893-1898. 10.1200/JCO.2008.19.2930.View ArticlePubMedGoogle Scholar
- Karavasilis V, Seddon BM, Ashley S, AI-Muderis O, Fisher C, Judson I: Significant clinical benefit of fierst-line palliative chemotherapy in advanced soft-tissue sarcoma. Cancer. 2008, 112: 1585-1591. 10.1002/cncr.23332.View ArticlePubMedGoogle Scholar
- Sleijfer S, Ouali M, Van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PCW, Verweiji J, Blay JY: Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the european organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTG-STBSG). Eur J Cancer. 2010, 46: 72-83. 10.1016/j.ejca.2009.09.022.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.